cmx-001 and Laryngeal-Diseases

To determine if brincidofovir, an oral analog of cidofovir that achieves high tissue levels of the active metabolite with low systemic toxicity, has an observable effect on HPV-related disease of the larynx.. Two patients with laryngeal recurrent respiratory papillomatosis (one each of genotypes 6 and 11) and 1 with recurring aryepiglottic fold. Brincidofovir reduced papilloma burden in 1 patient and markedly attenuated the rate and magnitude of recurrence in both. After surgical intervention, Patient 1 remains disease-free at 10 years (7 years from last intervention) and Patient 2 has no symptoms at 8 years. Patient 3 with recurring. Brincidofovir appears to attenuate HPV disease of the larynx in this small pilot study, though further investigation is required because of the highly variable nature of the disease and potential confounding factors.

Topics: Administration, Oral; Adult; Alphapapillomavirus; Antiviral Agents; Cytosine; Dose-Response Relationship, Drug; Humans; Laryngeal Diseases; Laryngoscopy; Larynx; Male; Middle Aged; Organophosphonates; Papillomavirus Infections; Pilot Projects